FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128732022> ?p ?o ?g. }

• W2128732022 endingPage "806" @default.
• W2128732022 startingPage "801" @default.
• W2128732022 abstract "Previous studies have shown that interferon-α (IFN-α) and chemotherapy is an effective treatment for patients with newly diagnosed follicular lymphoma. Therefore, we performed a phase II trial to determine the safety and effectiveness of IFN-α and standard doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy (IABVD) in these patients. Patients with newly diagnosed advanced stage classic Hodgkin lymphoma (HL) were enrolled between July 1997 and March 2000 on IABVD as initial therapy. This consisted of six cycles of ABVD with concurrent IFN-α followed by radiation therapy if indicated. IFN-α 6 million IU/m2 was administered subcutaneously daily for 3 days and on day 4 patients received IFN-α with ABVD. Courses were repeated every 2 weeks for a maximum of 12 courses. IFN-α dose reduction was allowed for cytopenia. Outcome and baseline characteristics were reported. Thirty patients (median age, 30 years [range, 18–62 years]) were evaluable. Patients had Ann Arbor stage II (7%), III (30%) or IV (63%) disease, and 47% were at intermediate or high risk, as defined by the International Prognostic Score (≤ 2 vs. > 2). The 3-year event-free survival rate was 71% (95% confidence interval [CI], 56–90%), and the 3-year overall survival rate was 96% (95% CI, 89–100%). Treatment was well tolerated, with only three patients requiring IFN-α dose reduction or discontinuation because of cytopenia. IABVD is an effective regimen against advanced HL and is well tolerated. However, because of the emergence of effective new biologic agents, further development of this regimen is not warranted." @default.
• W2128732022 created "2016-06-24" @default.
• W2128732022 creator A5006742031 @default.
• W2128732022 creator A5007688820 @default.
• W2128732022 creator A5021262821 @default.
• W2128732022 creator A5034301588 @default.
• W2128732022 creator A5060924118 @default.
• W2128732022 creator A5065054247 @default.
• W2128732022 creator A5068152076 @default.
• W2128732022 creator A5069576482 @default.
• W2128732022 creator A5070455368 @default.
• W2128732022 creator A5089736242 @default.
• W2128732022 date "2012-01-03" @default.
• W2128732022 modified "2023-10-05" @default.
• W2128732022 title "Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study" @default.
• W2128732022 cites W1972168709 @default.
• W2128732022 cites W1979093207 @default.
• W2128732022 cites W2002507218 @default.
• W2128732022 cites W2076334524 @default.
• W2128732022 cites W2087237648 @default.
• W2128732022 cites W2087704532 @default.
• W2128732022 cites W2093312029 @default.
• W2128732022 cites W2093767787 @default.
• W2128732022 cites W2095799532 @default.
• W2128732022 cites W2101995865 @default.
• W2128732022 cites W2115919161 @default.
• W2128732022 cites W2133201432 @default.
• W2128732022 cites W2136422032 @default.
• W2128732022 cites W2140801657 @default.
• W2128732022 cites W2158734599 @default.
• W2128732022 cites W2328676772 @default.
• W2128732022 cites W2494592270 @default.
• W2128732022 cites W4235766391 @default.
• W2128732022 doi "https://doi.org/10.3109/10428194.2011.631160" @default.
• W2128732022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22023528" @default.
• W2128732022 hasPublicationYear "2012" @default.
• W2128732022 type Work @default.
• W2128732022 sameAs 2128732022 @default.
• W2128732022 citedByCount "11" @default.
• W2128732022 countsByYear W21287320222012 @default.
• W2128732022 countsByYear W21287320222013 @default.
• W2128732022 countsByYear W21287320222015 @default.
• W2128732022 countsByYear W21287320222017 @default.
• W2128732022 countsByYear W21287320222023 @default.
• W2128732022 crossrefType "journal-article" @default.
• W2128732022 hasAuthorship W2128732022A5006742031 @default.
• W2128732022 hasAuthorship W2128732022A5007688820 @default.
• W2128732022 hasAuthorship W2128732022A5021262821 @default.
• W2128732022 hasAuthorship W2128732022A5034301588 @default.
• W2128732022 hasAuthorship W2128732022A5060924118 @default.
• W2128732022 hasAuthorship W2128732022A5065054247 @default.
• W2128732022 hasAuthorship W2128732022A5068152076 @default.
• W2128732022 hasAuthorship W2128732022A5069576482 @default.
• W2128732022 hasAuthorship W2128732022A5070455368 @default.
• W2128732022 hasAuthorship W2128732022A5089736242 @default.
• W2128732022 hasConcept C126322002 @default.
• W2128732022 hasConcept C141071460 @default.
• W2128732022 hasConcept C143998085 @default.
• W2128732022 hasConcept C2776232574 @default.
• W2128732022 hasConcept C2776305933 @default.
• W2128732022 hasConcept C2776694085 @default.
• W2128732022 hasConcept C2776755627 @default.
• W2128732022 hasConcept C2777058707 @default.
• W2128732022 hasConcept C2777132456 @default.
• W2128732022 hasConcept C2778336483 @default.
• W2128732022 hasConcept C2778496288 @default.
• W2128732022 hasConcept C2778715236 @default.
• W2128732022 hasConcept C2779020855 @default.
• W2128732022 hasConcept C2779338263 @default.
• W2128732022 hasConcept C2779429289 @default.
• W2128732022 hasConcept C2780007613 @default.
• W2128732022 hasConcept C2780366003 @default.
• W2128732022 hasConcept C2780964509 @default.
• W2128732022 hasConcept C2781413609 @default.
• W2128732022 hasConcept C71924100 @default.
• W2128732022 hasConcept C90924648 @default.
• W2128732022 hasConceptScore W2128732022C126322002 @default.
• W2128732022 hasConceptScore W2128732022C141071460 @default.
• W2128732022 hasConceptScore W2128732022C143998085 @default.
• W2128732022 hasConceptScore W2128732022C2776232574 @default.
• W2128732022 hasConceptScore W2128732022C2776305933 @default.
• W2128732022 hasConceptScore W2128732022C2776694085 @default.
• W2128732022 hasConceptScore W2128732022C2776755627 @default.
• W2128732022 hasConceptScore W2128732022C2777058707 @default.
• W2128732022 hasConceptScore W2128732022C2777132456 @default.
• W2128732022 hasConceptScore W2128732022C2778336483 @default.
• W2128732022 hasConceptScore W2128732022C2778496288 @default.
• W2128732022 hasConceptScore W2128732022C2778715236 @default.
• W2128732022 hasConceptScore W2128732022C2779020855 @default.
• W2128732022 hasConceptScore W2128732022C2779338263 @default.
• W2128732022 hasConceptScore W2128732022C2779429289 @default.
• W2128732022 hasConceptScore W2128732022C2780007613 @default.
• W2128732022 hasConceptScore W2128732022C2780366003 @default.
• W2128732022 hasConceptScore W2128732022C2780964509 @default.
• W2128732022 hasConceptScore W2128732022C2781413609 @default.
• W2128732022 hasConceptScore W2128732022C71924100 @default.
• W2128732022 hasConceptScore W2128732022C90924648 @default.
• W2128732022 hasIssue "5" @default.

• next